2. Search Result
Search Result
Results for "

cancer imaging

" in MedChemExpress (MCE) Product Catalog:

85

Inhibitors & Agonists

12

Fluorescent Dye

8

Biochemical Assay Reagents

25

Peptides

2

Inhibitory Antibodies

1

Isotope-Labeled Compounds

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153550
    PSMA-1007

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    PSMA-1007
  • HY-D1063
    IR-780
    3 Publications Verification

    		 Fluorescent Dye Cancer
    IR780 is a prototypic NIR heptamethine cyanine agent, with a high molar extinction coefficient. The maximum excitation wavelength of IR780 was 777-780 nm, and the maximum emission wavelength was 798-823 nm. IR780 can be used in cancer PTT/PDT and imaging .
    IR-780
  • HY-148761
    Zadavotide guraxetan
    2 Publications Verification

    PSMA I&T; PNT-2002

    		 PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    Zadavotide guraxetan
  • HY-137331
    FAPI-46
    1 Publications Verification

    		 FAP Cancer
    FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with 68Ga or 177Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .
    FAPI-46
  • HY-P5292A
    HYNIC-iPSMA TFA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P991650
    MDX1201

    		PSMA Cancer
    MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
    MDX1201
  • HY-158251
    BIBD-300

    		Others Cancer
    BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .
    BIBD-300
  • HY-P10943
    APO-15

    		Ser/Thr Kinase Inflammation/Immunology Cancer
    APO-15 is a fluorogenic imaging agent targeting phosphatidylserine (PS) exposed on the cell membrane of apoptotic cells. APO-15 can selectively bind to apoptotic cells, enabling staining and imaging of apoptotic cells in a calcium-independent and wash-free manner. APO-15 is promising for research of inflammatory diseases and cancers .
    APO-15
  • HY-175685
    FAP-IN-7

    		FAP Cancer
    FAP-IN-7 (Compound 5b) is a FAP18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .
    FAP-IN-7
  • HY-P5292
    HYNIC-iPSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA
  • HY-W1126504
    ETN029

    		Notch Cancer
    ETN029 is a DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .
    ETN029
  • HY-175730
    CB2R ligand-1

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology Cancer
    CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with Ki of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .
    CB2R ligand-1
  • HY-170779
    DOTA-NI-FAPI-04

    		FAP Cancer
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([ 68Ga]Ga/DOTA-NI-FAPI-04 and [ 177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
    DOTA-NI-FAPI-04
  • HY-141511
    Coppersensor 1
    15+ Cited Publications

    		 Fluorescent Dye Neurological Disease Cancer
    Coppersensor-1 (CS1) is a membrane-permeable fluorescent dye. Coppersensor-1 has a picomolar affinity for Cu + with high selectivity over competing cellular metalions. Coppersensor-1 as a probe, can selective and sensitive detection of copper(I) ions (Cu +) in biological samples, including live cells. Coppersensor-1 can be used for the research of imaging of severe diseases such as cancer, cardiovascular disorders and neurogenerative diseases .
    Coppersensor 1
  • HY-D2315
    Probe-Cys

    		Fluorescent Dye Cancer
    Probe-Cys is a water-soluble and selective near-infrared fluorescent probe for Cys (λex= 680 nm, λem=710 nm) that is not interfered by Hcy, GSH, and HS-. Probe-Cys can react with the stimulant 1,4-dimercaptothreitol (DTT) and the inhibitor N-ethylmaleimide (NEM) in HepG2 cells and zebrafish for the detection of endogenous Cys. Probe-Cys can also be used for imaging Cys in Arabidopsis thaliana. Probe-Cys provides a method for cancer diagnosis and exploration of plant sulfur metabolism .
    Probe-Cys
  • HY-175163
    TPAPyN

    		Photosensitizer Cancer
    TPAPyN is a nitroreductase(NTR)-responsive type I photosensitizer. TPAPyN facilitates the imaging of hypoxic cancer cells and image-guided photodynamic therapy (PDT). TPAPyN does not emit fluorescence in the aqueous environment, but restores when NTR cleaves the nitrofuran quencher with aggregation-induced emission. TPAPyN can be used as a fluorescent probe for specific imaging of hypoxic cancer .
    TPAPyN
  • HY-P9943
    Igovomab

    		Transmembrane Glycoprotein Cancer
    Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research .
    Igovomab
  • HY-176834
    3-Deoxy-3-fluoro-D-fructose

    		GLUT Cancer
    3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC50s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers .
    3-Deoxy-3-fluoro-D-fructose
  • HY-P10788
    CK3 peptide

    		Complement System Cancer
    CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.
    CK3 peptide
  • HY-P10744
    BQ7859

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7859
  • HY-174808
    SC691

    		PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer .
    SC691
  • HY-P5287
    cRGDfK-thioacetyl ester

    		Integrin Cancer
    cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
    cRGDfK-thioacetyl ester
  • HY-P11025
    TMVP1446

    		VEGFR Cancer
    TMVP1446 is a VEGFR-3 targeting peptide. TMVP1446 labeled with cyanine 7 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .
    TMVP1446
  • HY-P5287A
    cRGDfK-thioacetyl ester TFA

    		Integrin Cancer
    cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
    cRGDfK-thioacetyl ester TFA
  • HY-154844
    FAP Ligand 1

    		Biochemical Assay Reagents Cancer
    FAP Ligand 1 (FL), a high-affinity FAP small-molecule ligand, is used to target attached drugs to FAP-expressing fibroblasts and can be used in radiation imaging studies of targeted cancers .
    FAP Ligand 1
  • HY-160064
    SW1-A aptamer sodium

    		DNA Alkylator/Crosslinker Cancer
    SW1-A aptamer sodium is an optimized aptamer based on SW1 aptamer (HY-160063) that specifically targets liver cancer SMMC-7721 cells (Kd: 133.73 nM). SW1-A aptamer maintains strong affinity to liver cancer tissues and cells .
    SW1-A aptamer sodium
  • HY-160063
    SW1 aptamer sodium

    		Fluorescent Dye DNA Alkylator/Crosslinker Cancer
    SW1 aptamer sodium is a high-affinity DNA aptamer (Kd: 123.62 nM) that targets liver cancer SMMC-7721 cells and targets intracellular components within the nucleus. SW1 aptamer sodium can also identify various other types of cancer cells and tissues, serving as an effective molecular probe for clinical cancer diagnosis .
    SW1 aptamer sodium
  • HY-P11310
    PSMA-1-SMCC

    		PSMA Cancer
    PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA). PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer .
    PSMA-1-SMCC
  • HY-128643
    FAPI-4
    Maximum Cited Publications
    25 Publications Verification

    		 FAP Cancer
    FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. 68Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .
    FAPI-4
  • HY-149869
    PSMA-IN-3

    		PSMA Cancer
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
    PSMA-IN-3
  • HY-141637
    2-Deoxy-2-fluoro-D-glucose
    1 Publications Verification

    2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose

    		 Biochemical Assay Reagents Others
    2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.
    2-Deoxy-2-fluoro-D-glucose
  • HY-164475
    PARP1-IN-29

    		PARP Cancer
    PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .
    PARP1-IN-29
  • HY-164725
    FAPI-mFS

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-175612
    DOTA-ALB-01

    		FAP Cancer
    DOTA-ALB-01 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-01 labeled with 68Ga or 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention. DOTA-ALB-01 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-01
  • HY-173383
    DOPE-DOTA sodium

    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt

    		 Biochemical Assay Reagents Inflammation/Immunology Cancer
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-175613
    DOTA-ALB-02

    		FAP Cancer
    DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-02
  • HY-P10896
    NOTA-P2-RM26

    		Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-131326
    DOTA-tris(tBu)ester NHS ester

    		Biochemical Assay Reagents Cancer
    DOTA-tris(tBu)ester NHS ester is a DOTA-based chelator. DOTA-tris(tBu)ester NHS ester can efficiently chelate a variety of metal ions to form stable complexes suitable for cancer diagnosis, treatment and molecular imaging. DOTA-tris(tBu)ester NHS ester can significantly increase the loading capacity of metal ions through polymerization reaction, thereby enhancing the specific activity of imaging signals or radiotherapy. NHS ester can be used to label primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules .
    DOTA-tris(tBu)ester NHS ester
  • HY-D1876
    ZY-2

    		Fluorescent Dye Cancer
    ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells .
    ZY-2
  • HY-155486
    HCy-AAN-Bio

    		Fluorescent Dye Cancer
    HCy-AAN-Bio is a tumor-targeted hemicyanine (HCy) probe for Fluorescent/photoacoustic (FL/PA) imaging of legumain in vivo. Legumain can specifically cleave HCy-AAN-Bio with the generation of FL/PA signal. HCy-AAN-Bio is a powerful tool for early diagnosis of associated cancer .
    HCy-AAN-Bio
  • HY-150970
    ICy-OH

    		Pyroptosis Cancer
    ICy-OH, an iodinated photosensitizer, is an effective anticancer agent. ICy-OH can be used not only for deep tissue imaging (λex=640 nm，λem=690-740 nm) but also to selectively induce cell death in pancreatic cancer cells via cell pyroptosis pathway .
    ICy-OH
  • HY-19997
    Mannose triflate

    TATM

    		 Biochemical Assay Reagents Cancer
    Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .
    Mannose triflate
  • HY-134418
    NOTA

    		Radionuclide-Drug Conjugates (RDCs) Cardiovascular Disease Cancer
    NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .
    NOTA
  • HY-D1456
    TEPC466

    		Pyruvate Kinase Cancer
    TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research .
    TEPC466
  • HY-D1275
    CAY10731

    		Fluorescent Dye Others
    CAY10731 (compound 3) is a highly selective fluorescent probe for detection of hydrogen sulfide (H2S). CAY10731 is used to monitor exo- and endogenous H2S in both cancer and normal cells. CAY10731 is applied for imaging of H2S in living tissues at variable depths and in nematodes .
    CAY10731
  • HY-147865
    Apoptosis inducer 8

    		Galectin Apoptosis Cancer
    Apoptosis inducer 8 (Compound 7c) is a galectin-1 (gal-1) mediated apoptosis-inducing agent against global major leading lung cancer burden. Apoptosis inducer 8 significantly reduced the gal-1 protein level. Apoptosis inducer 8 is also a PET imaging agent .
    Apoptosis inducer 8
  • HY-P10292
    NOTA-Pep-1L

    		Radionuclide-Drug Conjugates (RDCs) Interleukin Related Cancer
    NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-Pep-1L
  • HY-139401
    FAPI-34
    1 Publications Verification

    		 FAP Cancer
    FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties. (patent WO2019154886A1).
    FAPI-34
  • HY-D2334
    AlF-NOTA-c-d-VAP

    		Radionuclide-Drug Conjugates (RDCs) HSP Cancer
    AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
    AlF-NOTA-c-d-VAP
  • HY-121659
    DCFBC

    		PSMA Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
    DCFBC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: